{"id":"nalfurafine-hcl-2-5-g","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nalfurafine binds to kappa opioid receptors, which are involved in the regulation of pruritus (itching). By activating these receptors, particularly in the spinal cord and brain regions responsible for itch sensation, the drug reduces the perception and transmission of itch signals. This mechanism makes it effective for treating chronic pruritus associated with conditions like uremia and atopic dermatitis.","oneSentence":"Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:40.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pruritus associated with chronic kidney disease"},{"name":"Pruritus associated with atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT00793156","phase":"PHASE3","title":"A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)","status":"UNKNOWN","sponsor":"Acologix, Inc.","startDate":"2009-12","conditions":"Uremic Pruritus","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Nalfurafine HCl 2.5 µg","genericName":"Nalfurafine HCl 2.5 µg","companyName":"Acologix, Inc.","companyId":"acologix-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system. Used for Chronic pruritus associated with chronic kidney disease, Pruritus associated with atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}